Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
This project shall be implemented through incorporation of a new joint venture company in Zambia
Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Subscribe To Our Newsletter & Stay Updated